Best Life Sciences Companies in Zurich, Switzerland

Developer of bioabsorbable synthetic heart valves and vascular grafts. The implants function as natural valves and vessels, allowing the body to heal. As the matrix gets absorbed over time, components of native tissue develop into functioning natural tissue. The flagship product is a replacement pulmonary valve for children with congenital heart malformations.

Funding rounds

• Dec 2025Venture Debt$43.6M
• Dec 2025Series D$11.6M
• Aug 2023Series D$13.7M
• Feb 2023Series D$34.2M

Founders & team

Eliane SchutteChief Executive Officer

Investors

European Investment Bank, China Grand Pharmaceutical and Healthcare, DaVita Venture Group, EQT, Invest-NL, Grand Pharm

Tech stack

Animate.CssAnime.JsApache Http ServerCookieyesExactmetricsFancybox

Company developing personalized skin tissue therapeutics for skin defect treatments. The company is pioneering a novel approach to personalized skin treatment, leveraging its proprietary technology to create customized skin grafts for various medical applications. With a strong foundation in regenerative medicine and tissue engineering, CUTISS aims to revolutionize skin surgery and improve patient outcomes.

Funding rounds

• Sep 2025Series C$39M
• May 2024Series C$27.5M
• Jan 2022Grant (prize money)$339.6K
• Dec 2020Grant (prize money)$61.4K

Founders & team

Daniela MarinoCo-Founder & CEOFabienne Hartmann-FritschCo-Founder

Investors

EIC Fund, Wyss Foundation, Cherry Bay Capital Group, GISEV, Zurcher Kantonalbank, Yellowstone Holding

Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. Rational molecular design, chemical synthesis and Virometix's proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability. Virometix Vaccines is a spin-out company from the University of Zurich.

Funding rounds

• Nov 2025Series C$15M
• Jul 2020Series B$8M
• Sep 2017Series A$1.3M
• May 2017Series A$5.1M

Founders & team

Anna SumerayCEO

Investors

Venture Kick

Developer of therapeutics for allergies and neurodegenerative diseases. It offers antibody therapies for Peanut allergy, pollen allergy, ALS, neuroinflammation, and Alzheimer's disease.

Funding rounds

• Aug 2025Series B$37M
• Sep 2024Grant (prize money)$1.5M
• May 2020Grant (prize money)$55.5K
• Dec 2019Grant (prize money)$55.1K

Founders & team

Alcide BarberisCEO

Investors

Europa, Admin, The ALS Association, Targetals, EIC Fund

Tech stack

PhpGoogle MapsBootstrapApache Http ServerJquery UiJquery

Developer of multispecific antibody therapeutics for inflammation and cancer. The company applies proprietary discovery and engineering platforms to generate antibody fragment-based candidates with tailored pharmacokinetic properties. Its pipeline includes first-in-class bispecific and multispecific drug candidates targeting inflammatory and oncological indications. The platform technology enables assembly of stable, highly potent antibody formats using modular building blocks. By leveraging scalable, reproducible engineering methods, the company accelerates therapeutic discovery and optimizes manufacturing characteristics.

Funding rounds

• Jan 2025Series C$55M
• May 2021Series C$111M
• Mar 2020Series B$23.5M
• Dec 2019Series B$15.2M

Founders & team

David UrechCEO

Investors

Mitsubishi UFJ Capital, Eisai Innovation, Sansheng Guojian Pharmaceutical, Novo Holdings, HBM Partners, Forbion

Tech stack

AosApache Http ServerCloudflareCloudflare Bot ManagementConstant ContactGoogle Analytics

Developer of therapeutic solutions for treating neurological disorders. The company has developed NOE-101 mGluR5 NAM that acts as a negative allosteric modulator of mGlu5 receptors for the treatment of seizures associated with tuberous sclerosis complex and for the management of pain associated with Trigeminal Neuralgia. It also provides NOE-105 PDE 10Ai for the treatment of Tourette syndrome, NOE-109 mGluR2/3 NAM, NOE-115 TRI, and others.

Funding rounds

• Dec 2024Series B$35M
• Mar 2023Series B$112M
• Dec 2020Series A$60M
• 2019Seed—

Founders & team

George GaribaldiPresident and Co-founder - head of Research and Development.

Investors

Sofinnova Partners, Forbion, Jeito, UPMC, Polaris Partners, Gilde Healthcare

Developer of biologics for selective degradation of disease-driving extracellular proteins. It focuses on precision therapeutics for autoimmune diseases by targeting circulating proteins, specifically autoantibodies. The company's platform enables rapid, selective, and deep degradation of target proteins without broad immunosuppression. This approach offers an improved safety profile and the potential for earlier disease intervention, which could improve patient quality of life and lower healthcare costs. The platform can target and degrade any circulating extracellular protein of interest, applicable to diseases driven by circulating proteins, such as autoimmune and neurological diseases.

Provider of temperature-controlled container solutions, monitoring, and ULD tracking services. The company delivers end-to-end supply chain management, real-time insights, and sustainability solutions. It offers container solutions, software, and related services. The company provides solutions for pharma containers, pharma monitoring, and ULD tracking. Services include lane risk assessment, delivery and pick up, and insurance.

Funding rounds

• Jun 2024Series D$116M
• Oct 2023Series C$57M
• Apr 2023Series C—
• Oct 2021Conventional Debt—

Founders & team

Nico RosCo-Founder & CTORichard EttlCEO

Investors

MVM, BCGE, Swiss, M&G, Catalyst, Tybourne Capital Management

Tech stack

Amazon SesAmazon Web ServicesApple Icloud MailAzureCloudflareCloudflare Bot Management

Developer of nanotechnology reagents and protocols for RNA and protein detection. The platform incorporates a nanotechnology-based signal amplification system. This system permits simultaneous multiplex target detection and is multimodal for applications like immunofluorescence and imaging mass cytometry. Designed for ease of use, it requires no specialized laboratory equipment. Scientific researchers in cell biology and genomics can perform accurate, high-throughput biomolecule quantification. This quantification complements other data analysis methods like RNA sequencing.

Funding rounds

• Nov 2025Seed$7.8M

Founders & team

Scott FraserCo-FounderKaspar BinzChairman of the board of directors & co-founderSimon RestrepoCo-Founder

Investors

ZEISS, Zurcher Kantonalbank

Developer of implantable battery-powered pump for removal of ascites. It has developed a pump technology which can have application across multiple disease areas. The first product alfapump is an implantable pump system that collects ascites as they form and moves them into the bladder. The pump can be charged wirelessly through the skin. Future applications include chronic pleural effusion and fluid overload due to congestive heart failure or renal disease.

Funding rounds

• Mar 2025Post IPO$11.5M
• Mar 2024Post IPO$12.5M
• Mar 2022Post IPO$30.9M
• Feb 2021Post IPO$27.1M

Founders & team

Ian CrosbieCEO

Investors

Partners In Equity, Life Sciences Partners, NeoMed, BioMedPartners, Entrepreneurs Fund, Capricorn Partners

Tech stack

Apache Http ServerChart.JsContact Form 7CookieyesCore-JsElementor

Developer of technology for endovascular catheter navigation and sensing. Its products include Flowcath, TrackCath, and CPS for minimally invasive cardiovascular procedures, providing the physician with salient information about the catheter’s position in respect to the side branches.

Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company has an HLA-based pipeline that includes first-in-class immunotherapies for the treatment of cancer and autoimmune diseases. The Company´s lead product candidate, IOS-1002, is an HLA-based protein that blocks the activation of three different immunosuppressive receptors (also known as checkpoints) on innate and adaptive immune cells

Funding rounds

• Sep 2024Series C$11M
• Jun 2022Series B$74M
• Dec 2019Series A$15.2M
• Oct 2018Series A—

Founders & team

Christoph RennerCo-Founder & CMOSean SmithCEO

Investors

Gimv, Pfizer, Mission BioCapital, BioMedPartners, Double Point Ventures, Samsara BioCapital